RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part ...
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback